William H. Collier is the Pres, CEO & Director at Arbutus Biopharma Corp.
As the Pres and CEO & Director of Arbutus Biopharma Corp, the total compensation of Mr Collier at Arbutus Biopharma Corp is $972,317. There are no executives at Arbutus Biopharma Corp getting paid more.
Mr Collier is 61, he's been the Pres and CEO & Director of Arbutus Biopharma Corp since . There are 5 older and 3 younger executives at Arbutus Biopharma Corp. The oldest executive at Arbutus Biopharma Corp is R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C, Q.C., 70, who is the Sec..
William's mailing address filed with the SEC is C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER, PA, 18974.
Over the last 10 years, insiders at Arbutus Biopharma Corp have traded over $2,165,982 worth of Arbutus Biopharma Corp stock and bought 1,000 units worth $6,950 . The most active insiders traders include Sciences Ltd. Roivant, Global Investors Lp Viking ..., and Andrew Lo. On average, Arbutus Biopharma Corp executives and independent directors trade stock every 164 days with the average trade being worth of $124,173. The most recent stock trade was executed by Keith S Manchester on 14 August 2024, trading 54,915 units of ABUS stock currently worth $30,752.
arbutus biopharma corporation (nasdaq:abus) is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis b infection, a disease of the liver caused by hepatitis b virus (hbv). we are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the hbv treatment landscape and cure hepatitis b virus disease. in addition to our hbv assets, we are developing a pipeline of programs that leverage our expertise in rna interference (rnai) therapeutics and our lipid nanoparticle (lnp) technology.
Arbutus Biopharma Corp executives and other stock owners filed with the SEC include: